Related Experiment Video
Updated: Jul 11, 2026

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
First case series on the use of imiquimod for morphoea
1Faculty of Medicine, University of Calgary, Calgary, Alberta T6G 2G3, Canada. research@mdskinhealth.com
Background:
Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta.
Objective:
Our objective was to use imiquimod 5% cream (Aldara), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea.
Methods:
Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months.
Results:
The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness.
Conclusion:
This is the first case series describing the successful application of imiquimod in the management of morphoea.
More Related Videos
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

